


MISSION IMPOSSIBLE: IF YOU CHOOSE TO ACCEPT MISSIO JOIN JUSTICE LEAGUE I'M POSSIBLE

HEPBURN

In 2017, an estimated 20.7 million people aged 12 or older needed substance use treatment. Stated another way, about 1 in 13 people aged 12 or older (7.6 percent) needed substance are tentament (<u>Figure 8</u>). About 10 million addacents aged 12 to 17 needed treatment for a substance use problem in the past year, representing 4.1 percent o addecents, or about 1 in 24 addrecents. About 52 million young adults aged 18 to 52 needed treatment for a substance use problem in the past year, representing 51.1 percent of young adults. Statel another way, about 1 in 7 young adults needed substance to the treatment for a substance to a policien and the past year. The percent is 51.1 percent of young adults. Statel another way, about 1 in 7 young adults needed substance to the treatment. About 54 million adults aged 156 or older needed substance to the tentiment in the past year. This number represents 65 percent of adults aged 150 or older, or about 1 in 15 adults in this age group.







<text><text><list-item><list-item><list-item><list-item>


OVERVIEW

Despite effective treatments, magnitude of the addiction related problems continue to grow # Opioid Crisis

- # Marijuana Use Up in Women, Alcohol Binge Drinking, Related Deaths, Disability continue to climb
- # <1:10 with Substance Use Disorders receive treatment
- # Stigma, MYTHS & Realities limit access to medical treatment for Substance Use Disorders
- # Remains easier to obtain alcohol, nicotine, heroin than medical treatment for addictions







SUD MEDICATIONS ARE NOT MORE DANGEROUS

LITHIUM

Low therapeutic index Renal Toxicity Tremors Diabetes Insipidus


ANTIPSYCHOTICS


Tardive Dyskinesia Agranulocytosis Metabolic Syndrom


MYTH: PATIENTS BECOME ADDICTED TO BUPRENORPHINE

PHARMCOLOGIC DEPENDENCE ≠LOSS OF CONTROL

- Buprenorphine blocks craving
- Medications improve treatment engagement and retention
- Use as prescribed does not = Compulsive use despite harm
- · Improves chances to work + care for self, family, kids








SUD RELAPSE PREVENTION MEDICATION OUTCOMES ARE SIMILAR TO OTHER CHRONIC DISEASE MEDICATIONS

- 30 days of insulin treatment doesn't cure diabetes
- · Blood pressure medications only work if person continues to take them
- Although three medications are FDA approved for opioid use disorder,
 - <30% of addiction treatment programs offer medications
 - <50% eligible patients ever receive medications

Myth	Reality	Possible Policy Response
Buprenorphine treatment is more dangerous than oth- er chronic disease man- agement.	Buprenorphine treatment is simpler than many other routine treatments in primary care, such as titrating insulin or starting anticoagulation. But physicians receive little training in it.	Amend federal buprenorphine-treatment eligibili- ty requirements to include training completed during medical school and require training during medical school or residency. Add com- petency questions to U.S. Medical Licensing Examination and other licensing exams.
Use of buprenorphine is sim- ply a "replacement" addic- tion.	Addiction is defined as compulsively using a drug despite harm. Taking a prescribed medication to manage a chronic illness does not meet that definition.	Public health campaign to reduce stigma associ- ated with addiction treatment, similar to past campaigns (e.g., HIV) that provided educa- tion and challenged common myths.
Detoxification for opioid use disorder is effective.	There are no data showing that detoxifica- tion programs are effective at treating opioid use disorder. In fact, these inter- ventions may increase the likelihood of overdose death by eliminating tolerance.	Advocacy from professional physician organiza- tions to educate federal and state agencies and policymakers about evidence-based treat- ment and the lack of evidence for short-term "detoxification" treatment.
Prescribing buprenorphine is time consuming and bur- densome.	Treating patients with buprenorphine can be uniquely rewarding. In-office inductions and intensive behavioral therapy are not required for effective treatment.	Develop and disseminate protocols for primary care settings that emphasize out-of-office in- duction and treatment.
Reducing opioid prescribing alone will reduce overdose deaths.	Despite decreasing opioid prescribing, over- dose mortality has increased. Patients with opioid use disorder may shift to the illicit drug market, where the risk of over- dose is higher.	Develop a national system of virtual consultation for physicians to reach addiction and pain specialists who can support treatment of pa- tients with suspected opioid use disorder.



#RESPECT = SPECIAL POWERS MEDICATIONS ASSIST TREATMENT (MAT)

- # Recovery skills improve with relapse prevention medications
- #Empathy, family, friends, sponsors, peers and communities enhance treatment engagement
- #Self-Help + Groups + 1:1 Interventions help build recovery skills
- ${}^{\#}P{}^{revent} \text{ withdrawal, relapse and overdose with FDA approved medications}$
- $\# E {\rm ducate \ self \ \& \ others \ how \ established \ medical \ treatments \ improve \ remission}$
- #Clinical health emphasis reduces medical complications and overdose deaths
- #Treat Addictions Save Lives

